Sign up USA
Proactive Investors - Run By Investors For Investors

Maxim Group enthusiastic about Actinium Pharmaceuticals' innovative leukemia drug pipeline

Actinium stands out among pharmaceutical companies offering treatments that target the protein CD33 in leukemia patients
Cancer cells
Actinium's valuation should 'continue to rise' says the analyst

Maxim Group’s Jason McCarthy is bullish on cancer specialist Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) on the strength of its leukemia drug pipeline and commercial outlook.

McCarthy expects shares of Actinium Pharmaceuticals, which trade below $1, to rise higher in coming months thanks to a “catalyst-driven” second half.

“We believe valuation should continue to rise and drive shareholder value,” he wrote in a note to investors.

Of particular importance on the list of Actinium's research advances is its launch of a Phase 1 study of Actimab-A, its cancer-fighting treatment, which will be taken in combination with salvage chemotherapy by patients with relapsed or refractory acute myeloid leukemia.

The study will look at whether a single dose of Actimab-A, which targets the protein CD33, slashes cancer levels after patients have been treated with salvage chemotherapy, meaning patients who have not responded to other treatments.

Read: Actinium Pharmaceuticals gets healthy price target from Oppenheimer analysts

Actinium stands out among the pharmaceutical companies offering treatments that target CD33 as it has the only "radio-labeled" CD33, which may be"more efficacious and safer," according to McCarthy.

To treat AML, researchers have to target a specific protein, CD33, that's also expressed on healthy cells. The therapy has to be finely-tuned as it cannot attack the cancer without causing damage to the residual normal bone marrow.

Another positive, according to McCarthy, is that in a Phase 2 study, its drug Actimab-A demonstrated an overall response rate of 69% in patients with recently-diagnosed cases of acute myeloid leukemia.

A round of financing last March should extend Actinium’s cash runway until late next year, according to McCarthy.

The pharma group shares are likely to continue to rise, springing off of a 52-week low, which McCarthy blames on a "lack of catalysts" as well as its financing last March. "The latter we view as a 'smart' financing that should extend the cash runway to late 2019 and through multiple catalysts," McCarthy wrote.

A busy end of the year on the research level, which includes the American Society of Hematology's annual meeting in San Diego, California, in December, should throw up additional "catalysts" to push up Actinium's valuation.

As a result, McCarthy is keeping a Buy rating and a US$3 price target on the clinical-stage New York-based biotech firm.

Actinium shares were down slightly at 1% in afternoon trade to US$0.48.

View full ATNM profile View Profile

Actinium Pharmaceuticals Inc Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use